Literature DB >> 11942449

The effectiveness of blood tests in detecting secondary osteoporosis or mimicking conditions in postmenopausal women.

Alun Cooper1, Sarah Brew, Simon de Lusignan.   

Abstract

The National Service Framework for Older People requires a reduction in the number of falls that result in serious injury. Those most at risk need to be identified, investigated in line with the Royal College of Physicians Clinical Guidelines and receive appropriate treatment. This report looks at the results of investigation of postmenopausal women diagnosed as having osteoporosis in primary care by forearm Dexa scanner (DTX200) and questions whether the investigations suggested within the National Service Framework are justifiable. Scans were performed on 699 postmenopausal women aged 54 or over resulting in a new diagnosis of osteoporosis in 173 women. Complete blood tests were performed in 107 of the newly diagnosed patients. Only three of these patients (2.8%) had blood test results that revealed a potential secondary cause. The rates of positive findings are low; further research is needed to see if they are justified in postmenopausal women.

Entities:  

Mesh:

Year:  2002        PMID: 11942449      PMCID: PMC1314273     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  3 in total

1.  The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis.

Authors:  F E McKiernan; R L Berg; J G Linneman
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

2.  Utility of biochemical screening in the context of evaluating patients with a presumptive diagnosis of osteoporosis.

Authors:  C Rajeswaran; J Spencer; J H Barth; S M Orme
Journal:  Clin Rheumatol       Date:  2006-05-11       Impact factor: 2.980

3.  Improving Osteoporosis Management in Primary Care: An Audit of the Impact of a Community Based Fracture Liaison Nurse.

Authors:  Tom Chan; Simon de Lusignan; Alun Cooper; Mary Elliott
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.